Loading clinical trials...

A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 1NCT01209195

A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers

This study was a Phase 1 and pharmacologic open-labeled dose-escalation trial of MM-121 in combination with paclitaxel using a "3+3" design.

Lead sponsor: Merrimack Pharmaceuticals•5 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment41

Start dateOct 2010

Last updatedSep 8, 2016

Condition

Primary Peritoneal Cancer or Endometrial Cancer

Locations shown

University of Alabama at Birmingham Comprehensive Cancer Center

Birmingham, Alabama

Pinnacle Oncology Hematology

Scottsdale, Arizona

Comprehensive Blood and Cancer Center

Bakersfield, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 8, 2016Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions